Keytruda (pembrolizumab) is an immunotherapy given through a vein, most often every 3 or 6 weeks in an infusion clinic. A single Keytruda infusion usually runs about 30 minutes, plus time for check-in, lab work, and an exam. It does not kill cancer cells directly. Instead, it blocks a protein called PD-1 so your own T cells can recognize and attack tumor cells. That mechanism also explains the main safety concern: an immune system that is working harder can inflame healthy organs, so new symptoms need to be reported quickly rather than waited out.
The Short Version
- What it is: an anti-PD-1 antibody (a lab-made protein that releases a brake on immune cells).
- How it is given: intravenous infusion over roughly 30 minutes, on a repeating schedule set by your oncologist.
- Main risk: immune-related inflammation of the lungs, bowel, liver, skin, kidneys, or hormone glands.
- Urgent signs: new shortness of breath, persistent diarrhea, yellowing eyes, severe fatigue, or chest pain.
- Not a cure-all: use depends on tumor type and biomarker testing, and response varies widely between people.
How Pembrolizumab Works Against Cancer
Healthy immune cells carry a checkpoint protein called PD-1. Many tumors display a matching protein, PD-L1, which presses that checkpoint and switches the immune attack off. Pembrolizumab sits on PD-1 and prevents that handshake. T cells stay switched on and can keep targeting cancer cells.
Because the drug works on the immune system rather than on one tumor pathway, it has been approved for many cancer types, sometimes alone and sometimes combined with chemotherapy or other drugs. Eligibility often depends on test results: PD-L1 expression scores, or markers such as MSI-H or dMMR (signs that a tumor struggles to repair its own DNA). Those tests help predict who is more likely to benefit, though they are not guarantees.
Treatment length also varies. For some indications the labeling describes continuing until the cancer progresses or side effects become unacceptable; for others, a defined limit such as 24 months applies. Your oncologist chooses based on the approved use, your scans, and how you tolerate therapy.
Why it matters: response and duration differ by cancer type, so general survival numbers you read online may not apply to your situation.
What Happens During a Keytruda Infusion Appointment
Most visits follow a predictable rhythm. Knowing the order helps caregivers plan the day and spot anything unusual.
- Labs first: blood is drawn to check blood counts, liver enzymes, kidney function, and often thyroid hormones.
- Symptom review: a nurse or clinician asks about breathing, bowel habits, rashes, energy, and appetite since the last cycle.
- Approval to proceed: if labs or symptoms suggest inflammation, the cycle may be delayed while the team investigates.
- Infusion: the diluted drug is given through an IV line or port, typically over about 30 minutes.
- Observation: staff watch for infusion reactions such as fever, chills, flushing, or wheezing.
- Scheduling: the next cycle and any scans are booked before you leave.
A subcutaneous (under-the-skin) version of pembrolizumab has also been approved in the United States. Whether it is offered depends on your treatment plan, the clinic, and your insurance or payment arrangements, so ask the team directly rather than assuming one route is available.
Many people feel well enough to drive themselves home. Still, a companion is useful for the first cycle, since reactions are most likely then and fatigue can arrive later in the day.
Immune-Related Side Effects and the Red Flags That Matter
The most important safety theme with checkpoint inhibitors is inflammation in healthy tissue. US prescribing information for pembrolizumab describes immune-mediated reactions that can affect nearly any organ, including pneumonitis (lung inflammation), colitis (bowel inflammation), hepatitis, nephritis, severe skin reactions, and endocrine problems such as thyroid disease, adrenal insufficiency, hypophysitis, and type 1 diabetes. Serious infusion reactions and complications after allogeneic stem cell transplant are also described. Full labeling for approved products is published through the FDA’s drug database at Drugs@FDA.
These events can start during treatment or weeks to months after the last dose. That delayed pattern is why oncology teams ask patients to report symptoms even after therapy ends.
Call the oncology team the same day for
- Breathing changes: new cough, breathlessness, or chest tightness.
- Gut symptoms: diarrhea several times a day, blood in stool, or severe cramping.
- Liver signs: yellow eyes or skin, dark urine, or right-sided belly pain.
- Hormone signs: deep fatigue, dizziness, unusual thirst, confusion, or rapid weight change.
- Skin reactions: spreading rash, blisters, or peeling, especially with mouth sores.
Call 911 or go to an emergency department for severe breathlessness, chest pain, collapse, high fever with shaking chills, or a rash with blistering and fever. When you arrive, say clearly that you are receiving immunotherapy, because treatment for immune-related inflammation often involves corticosteroids rather than standard supportive care alone. The National Cancer Institute keeps a plain-language overview of immunotherapy side effects that many families find useful between visits.
Milder effects are common too: tiredness, joint aches, itching, nausea, and reduced appetite. Report them anyway. Early, mild colitis is easier to manage than colitis found after a week of ignored symptoms.
Does Immunotherapy Weaken the Immune System?
Not in the way chemotherapy can. Pembrolizumab does not primarily suppress bone marrow or routinely drive neutrophil counts down. It removes a brake, so the usual problem is an immune system that is too active, not too weak.
There are two important caveats. First, corticosteroids or other immune-suppressing drugs used to treat a serious immune-related reaction do lower infection defenses while you take them. Second, many people receive pembrolizumab alongside chemotherapy, and the chemotherapy component can reduce blood counts. Fever during treatment should always be reported promptly, because the cause may be infection, inflammation, or both.
Blood clots are another frequent question. Cancer itself raises clot risk, and surgery, immobility, and central lines add to it. Research on checkpoint inhibitors and venous thromboembolism is still developing, so treat any new leg swelling, calf pain, sudden breathlessness, or chest pain as urgent rather than trying to assign a cause at home.
How Pembrolizumab Compares With Other Checkpoint Inhibitors
Several checkpoint drugs share the same broad idea but differ in target, schedule, and approved uses. Nivolumab also blocks PD-1. Atezolizumab and durvalumab block PD-L1 instead. Ipilimumab blocks a different checkpoint, CTLA-4, and is often combined with a PD-1 drug, which raises both response and toxicity.
Three practical differences matter more than the biology:
- Approved indications: each drug is cleared for specific tumor types, stages, and biomarker profiles.
- Dosing interval: schedules range from every 2 weeks to every 6 weeks depending on the drug and the regimen.
- Combination partner: pairing with chemotherapy or a second immune drug changes the side effect profile.
Switching between these agents is not a simple swap. If you are comparing options for a gastrointestinal, lung, or other cancer, ask your oncologist to explain why one agent and interval fits your tumor’s test results. That conversation is more useful than head-to-head numbers from different trials with different patient groups.
Caregiver Support Between Appointments
Caregivers often notice problems first. Energy, appetite, mood, and bathroom habits change at home, not in the clinic chair.
A simple symptom log helps. Note the date, the symptom, how severe it is, and whether it is getting worse. Bring it to each visit. Many teams also provide an after-hours phone number; put it in your phone before you need it.
Quick tip: keep a card in your wallet that lists the immunotherapy name, start date, and your oncology clinic’s phone number.
Practical help matters as much as medical tracking. Plan lighter days after each Keytruda infusion, since fatigue often builds over a cycle. Keep a thermometer at home. Stock easy foods for low-appetite days. And protect your own rest; caregiving over months of treatment is a marathon, and clinic social workers can usually point to transportation, nutrition, and counseling resources.
Access, Brand Status, and Cost Conversations
Pembrolizumab is a prescription biologic administered by health professionals, not a pill you pick up and take at home. In the US it is usually billed through a medical benefit, which means the cancer center, specialty infusion pharmacy, and your plan coordinate authorization before the first cycle. Ask the financial navigator at your treatment center early; they handle prior authorizations and can explain copay structures and manufacturer or foundation assistance programs.
Pricing for brand and generic medicines does differ between countries, and some patients ask whether cross-border options apply. For infused oncology drugs, treatment is tied to the clinic that administers and monitors it, so this is a question for your care team first. Border Free Health is an online prescription referral service that works with certified, accredited pharmacy partners, and any prescription medication requires a valid prescription from the patient’s own prescriber.
Supportive medicines prescribed alongside immunotherapy, such as thyroid replacement or anti-nausea drugs, are a different conversation and may be filled through ordinary retail or mail channels.
Questions Worth Asking at the Next Visit
- Why this drug: what test result supports using a PD-1 inhibitor for my cancer?
- Schedule and duration: how often will I come in, and for how long?
- Monitoring plan: which labs and scans track response and organ inflammation?
- Symptom thresholds: how many loose stools, or what degree of breathlessness, triggers a call?
- After-hours contact: who answers nights and weekends, and what should I tell them?
- Vaccines and dental work: what is safe during treatment?
- If I stop: what happens next if side effects force a pause or a switch?
Write the answers down. Treatment decisions get easier when the plan, the warning signs, and the phone numbers are all in one place that any family member can find.
This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified clinician or pharmacist about your situation, and seek urgent care or call your local emergency number for severe or worsening symptoms.
